Type of CEBPA mutations in acute myeloid leukemia and their effect on prognosis
10.3760/cma.j.cn121090-20240316-00098
- VernacularTitle:急性髓系白血病中CEBPA基因突变的类型及其对预后的影响
- Author:
Yueying MAO
1
;
Hao CAI
;
Xinxin CAO
;
Jun FENG
;
Lu ZHANG
;
Daobin ZHOU
;
Jian LI
Author Information
1. 中国医学科学院、北京协和医学院北京协和医院血液内科，北京 100730
- Keywords:
Leukemia, myeloid, acute;
CEBPA gene mutation;
Clinical characteristics;
Prognosis
- From:
Chinese Journal of Hematology
2024;45(6):556-560
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To demonstrate the type of CEBPA gene mutations among patients with acute myeloid leukemia (AML), clinical characteristics, and prognostic effect on patient outcomes.Methods:Demographic data, clinical features, laboratory characteristics, and data about treatment and follow-up of 57 patients with CEBPA mutated AML diagnosed at Peking Union Medical College Hospital between April 2016 and November 2022 were collected and analyzed.Results:In total, 57 patients with CEBPA mutation accounted for 16.1% of all the 353 patients with AML, among which 28 patients had CEBPA-bZIPinf and 29 had CEBPA-other. Compared with the CEBPA-other group, the CEBPA-bZIPinf group was younger (54 vs 64 years, P=0.010), de novo AML was more common ( P=0.001), and the level of bone marrow blast was higher (68.0% vs 36.3%, P=0.001). Moreover, 24 patients from the CEBPA-bZIPinf group and 19 from the CEBPA-other group received chemotherapy. The one-course complete remission (CR) rate of the CEBPA-bZIPinf group was significantly higher than that of the CEBPA-other (87.5% vs 47.4%, P=0.010) and CEBPA-wt (87.5% vs 50.3%, P=0.002) groups. After a median follow-up of 11 months, the median OS of the CEBPA-bZIPinf group was significantly longer than that of the CEBPA-wt group (not reached vs 22.1 months, P=0.012) . Conclusion:CEBPA-bZIPinf mutated AML is a unique clinical entity, with a younger age of diagnosis, better response to chemotherapy, and better prognosis.
